ZyVersa Therapeutics, Inc.

ZVSA

None; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001859007

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $347,901
Warnings	dilution, late filer, thin data not computable: short runway, degenerate inputs, distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 31, 2026 218 days before the rescan; latest periodic filing 10-Q received May 13, 2026
Last close	$0.30 2025-07-16; market equity $2.4M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

references in this report to "ZyVersa," the "Company," "we," "us," or "our" mean ZyVersa Therapeutics, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates. are a clinical stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. Our mission is to develop drugs that optimize health outcomes and improve patients' have two proprietary globally licensed drug development platforms, each of which was discovered by research scientists at the University of Miami, Miller School of Medicine (the "University of Miami" or "University").

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 1.9						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(189.4%)	(6.6%)		1.9	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 100.0						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Altman Z double-prime	(2,016.24)	(0.35)	100.0	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	0.03x	2.92x	100.0	828	2025-12-31
Growth and financing, sleeve percentile 94.5					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 0					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(85.7%)	2.2%	100.0	697	2025-12-31
Net share issuance, one year	215.2%	2.5%	89.1	632	2026-03-25

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 215.2%
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2025-07-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	not computable	(2.2%)	
Distance from 52-week high	(43.3%)	(29.8%)	34
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(0.9%)	
Book value to price	(5.60)	0.28	0
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	not computable	(0.19)	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Days since last periodic filing	175 (10-Q received May 13, 2026)
Median daily dollar volume, 63 sessions	$0

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$25.0M	2025-12-31	2026-03-31	10-K	26-014271
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$5.1M	2025-12-31	2026-03-31	10-K	26-014271
3	assets	us-gaap:Assets	$347,901	2025-12-31	2026-03-31	10-K	26-014271
4	assets	us-gaap:Assets	$20.6M	2024-12-31	2026-03-31	10-K	26-014271
5	current assets	us-gaap:AssetsCurrent	$347,901	2025-12-31	2026-03-31	10-K	26-014271
6	current liabilities	us-gaap:LiabilitiesCurrent	$12.7M	2025-12-31	2026-03-31	10-K	26-014271
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$137.6M	2025-12-31	2026-03-31	10-K	26-014271
8	operating income	us-gaap:OperatingIncomeLoss	-$25.5M	2025-12-31	2026-03-31	10-K	26-014271
9	book equity	us-gaap:StockholdersEquity	-$12.4M	2025-12-31	2026-03-31	10-K	26-014271
10	liabilities	us-gaap:Liabilities	$12.7M	2025-12-31	2026-03-31	10-K	26-014271
11	assets	us-gaap:Assets	$22.1M	2023-12-31	2025-03-27	10-K	25-000862
12	assets	us-gaap:Assets	$118.5M	2022-12-31	2024-03-25	10-K	24-011073
13	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,095,921	2026-03-25	2026-03-31	10-K	26-014271
14	shares outstanding	dei:EntityCommonStockSharesOutstanding	2,568,191	2025-03-20	2025-03-27	10-K	25-000862

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.